Bisphosphonate-based molecules as potential new antiparasitic drugs
Autor(a) principal: | |
---|---|
Data de Publicação: | 2020 |
Outros Autores: | , , , , , , , |
Tipo de documento: | Outros |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10362/116627 |
Resumo: | Neglected tropical diseases such as Chagas disease and leishmaniasis affect millions of people around the world. Both diseases affect various parts of the globe and drugs traditionally used in therapy against these diseases have limitations, especially with regard to low efficacy and high toxicity. In this context, the class of bisphosphonate-based compounds has made significant advances regarding the chemical synthesis process as well as the pharmacological properties attributed to these compounds. Among this spectrum of pharmacological activity, bisphosphonate compounds with antiparasitic activity stand out, especially in the treatment of Chagas disease and leishmaniasis caused by Trypanosoma cruzi and Leishmania spp., respectively. Some bisphosphonate compounds can inhibit the mevalonate pathway, an essential metabolic pathway, by interfering with the synthesis of ergosterol, a sterol responsible for the growth and viability of these parasites. Therefore, this review aims to present the information about the importance of these compounds as antiparasitic agents and as potential new drugs to treat Chagas disease and leishmaniasis. |
id |
RCAP_708da13fadbcb7c4c86f42673ba86997 |
---|---|
oai_identifier_str |
oai:run.unl.pt:10362/116627 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Bisphosphonate-based molecules as potential new antiparasitic drugsBisphosphonateChagas diseaseFarnesyl pyrosphosphate synthaseLeishmaniasisNeglected tropical diseasesChemistry (miscellaneous)Molecular MedicinePharmaceutical ScienceDrug DiscoveryParasitologySDG 3 - Good Health and Well-beingNeglected tropical diseases such as Chagas disease and leishmaniasis affect millions of people around the world. Both diseases affect various parts of the globe and drugs traditionally used in therapy against these diseases have limitations, especially with regard to low efficacy and high toxicity. In this context, the class of bisphosphonate-based compounds has made significant advances regarding the chemical synthesis process as well as the pharmacological properties attributed to these compounds. Among this spectrum of pharmacological activity, bisphosphonate compounds with antiparasitic activity stand out, especially in the treatment of Chagas disease and leishmaniasis caused by Trypanosoma cruzi and Leishmania spp., respectively. Some bisphosphonate compounds can inhibit the mevalonate pathway, an essential metabolic pathway, by interfering with the synthesis of ergosterol, a sterol responsible for the growth and viability of these parasites. Therefore, this review aims to present the information about the importance of these compounds as antiparasitic agents and as potential new drugs to treat Chagas disease and leishmaniasis.Instituto de Higiene e Medicina Tropical (IHMT)Global Health and Tropical Medicine (GHTM)Vector borne diseases and pathogens (VBD)RUNBranco Santos, Joice Castelode Melo, Jonathas AlvesMaheshwari, Swetade Medeiros, Wendy Marina Toscano Queirozde Freitas Oliveira, Johny WysllasMoreno, Cláudia JassicaMario Amzel, L.Gabelli, Sandra B.Sousa Silva, Marcelo2021-05-01T22:52:53Z2020-06-032020-06-03T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/other20application/pdfhttp://hdl.handle.net/10362/116627engPURE: 26669253https://doi.org/10.3390/molecules25112602info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-05-22T17:52:30Zoai:run.unl.pt:10362/116627Portal AgregadorONGhttps://www.rcaap.pt/oai/openairemluisa.alvim@gmail.comopendoar:71602024-05-22T17:52:30Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Bisphosphonate-based molecules as potential new antiparasitic drugs |
title |
Bisphosphonate-based molecules as potential new antiparasitic drugs |
spellingShingle |
Bisphosphonate-based molecules as potential new antiparasitic drugs Branco Santos, Joice Castelo Bisphosphonate Chagas disease Farnesyl pyrosphosphate synthase Leishmaniasis Neglected tropical diseases Chemistry (miscellaneous) Molecular Medicine Pharmaceutical Science Drug Discovery Parasitology SDG 3 - Good Health and Well-being |
title_short |
Bisphosphonate-based molecules as potential new antiparasitic drugs |
title_full |
Bisphosphonate-based molecules as potential new antiparasitic drugs |
title_fullStr |
Bisphosphonate-based molecules as potential new antiparasitic drugs |
title_full_unstemmed |
Bisphosphonate-based molecules as potential new antiparasitic drugs |
title_sort |
Bisphosphonate-based molecules as potential new antiparasitic drugs |
author |
Branco Santos, Joice Castelo |
author_facet |
Branco Santos, Joice Castelo de Melo, Jonathas Alves Maheshwari, Sweta de Medeiros, Wendy Marina Toscano Queiroz de Freitas Oliveira, Johny Wysllas Moreno, Cláudia Jassica Mario Amzel, L. Gabelli, Sandra B. Sousa Silva, Marcelo |
author_role |
author |
author2 |
de Melo, Jonathas Alves Maheshwari, Sweta de Medeiros, Wendy Marina Toscano Queiroz de Freitas Oliveira, Johny Wysllas Moreno, Cláudia Jassica Mario Amzel, L. Gabelli, Sandra B. Sousa Silva, Marcelo |
author2_role |
author author author author author author author author |
dc.contributor.none.fl_str_mv |
Instituto de Higiene e Medicina Tropical (IHMT) Global Health and Tropical Medicine (GHTM) Vector borne diseases and pathogens (VBD) RUN |
dc.contributor.author.fl_str_mv |
Branco Santos, Joice Castelo de Melo, Jonathas Alves Maheshwari, Sweta de Medeiros, Wendy Marina Toscano Queiroz de Freitas Oliveira, Johny Wysllas Moreno, Cláudia Jassica Mario Amzel, L. Gabelli, Sandra B. Sousa Silva, Marcelo |
dc.subject.por.fl_str_mv |
Bisphosphonate Chagas disease Farnesyl pyrosphosphate synthase Leishmaniasis Neglected tropical diseases Chemistry (miscellaneous) Molecular Medicine Pharmaceutical Science Drug Discovery Parasitology SDG 3 - Good Health and Well-being |
topic |
Bisphosphonate Chagas disease Farnesyl pyrosphosphate synthase Leishmaniasis Neglected tropical diseases Chemistry (miscellaneous) Molecular Medicine Pharmaceutical Science Drug Discovery Parasitology SDG 3 - Good Health and Well-being |
description |
Neglected tropical diseases such as Chagas disease and leishmaniasis affect millions of people around the world. Both diseases affect various parts of the globe and drugs traditionally used in therapy against these diseases have limitations, especially with regard to low efficacy and high toxicity. In this context, the class of bisphosphonate-based compounds has made significant advances regarding the chemical synthesis process as well as the pharmacological properties attributed to these compounds. Among this spectrum of pharmacological activity, bisphosphonate compounds with antiparasitic activity stand out, especially in the treatment of Chagas disease and leishmaniasis caused by Trypanosoma cruzi and Leishmania spp., respectively. Some bisphosphonate compounds can inhibit the mevalonate pathway, an essential metabolic pathway, by interfering with the synthesis of ergosterol, a sterol responsible for the growth and viability of these parasites. Therefore, this review aims to present the information about the importance of these compounds as antiparasitic agents and as potential new drugs to treat Chagas disease and leishmaniasis. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020-06-03 2020-06-03T00:00:00Z 2021-05-01T22:52:53Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/other |
format |
other |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10362/116627 |
url |
http://hdl.handle.net/10362/116627 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
PURE: 26669253 https://doi.org/10.3390/molecules25112602 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
20 application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
mluisa.alvim@gmail.com |
_version_ |
1817545794535817216 |